Gonococcal infection of musculoskeletal system, unspecified
ICD-10 A54.40 is a billable code used to indicate a diagnosis of gonococcal infection of musculoskeletal system, unspecified.
Gonococcal infection of the musculoskeletal system is a rare but serious complication of Neisseria gonorrhoeae infection, primarily known as a sexually transmitted infection (STI). This condition can manifest as septic arthritis or tenosynovitis, often affecting the knees, wrists, and ankles. Patients may present with joint pain, swelling, and fever, typically following a history of gonococcal urethritis or cervicitis. The infection can lead to significant morbidity if not promptly diagnosed and treated. Diagnosis is confirmed through culture or nucleic acid amplification tests (NAAT) from joint fluid or other relevant sites. Treatment typically involves the use of antibiotics, with ceftriaxone being the first-line therapy. Due to the potential for systemic spread, early identification and management are crucial to prevent long-term joint damage and complications.
Detailed history of infection, including sexual history and previous STIs.
Patients presenting with joint pain and a history of gonorrhea.
Ensure all relevant tests and treatments are documented to support the diagnosis.
Comprehensive joint examination findings and laboratory results.
Patients with acute arthritis symptoms and a history of gonococcal infection.
Differentiation from other inflammatory arthritides is crucial.
Used for confirming gonococcal infection in patients with joint symptoms.
Document the reason for testing and the results.
Infectious disease specialists may require additional testing for co-infections.
Common symptoms include joint pain, swelling, fever, and sometimes skin lesions. The affected joints are often painful and may show signs of inflammation.
Diagnosis is typically made through a combination of clinical evaluation, joint fluid analysis, and cultures or NAAT for Neisseria gonorrhoeae.
The first-line treatment is usually a combination of ceftriaxone and azithromycin, depending on local resistance patterns and guidelines.
